ARM

ARM Holdings

Fundamental data last updated:April 13, 2026

company profile

SECTOR

Technology

industry

Semiconductors

Exchange

Nasdaq

County of HQ

Canada

Next Earnings Date

05/06/26

Business Summary

Bright Minds Biosciences operates as a clinical-stage biotechnology company focused on developing novel therapeutics, generating value primarily through intellectual property creation and drug pipeline advancement rather than current product sales. Cash flow is presently driven by capital raises rather than commercial revenue, with enterprise value tied to the probability-adjusted success of its clinical assets. Its competitive moat, if realized, would stem from proprietary compounds, patents, and regulatory exclusivity in niche therapeutic areas. Success depends on translating early-stage science into late-stage approvals, at which point pricing power and exclusivity could generate high-margin pharmaceutical cash flows.

VALUATION

P/E

200

Market Cap ($M USD)

$158,163

Forward P/E

69.6

PEG

-

PRICE TO SALES

34

PRICE TO BOOK

20.3

EV / EBITDA

140.3

5-Year Average P/E

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

$0.75

Next Year EPS Growth Estimate

$2.14

Next Year Revenue Growth Estimate

20.70%

Return on Equity (ROE)

10.30%

Operating Margin

18.80%

Debt-to-Equity

0.1

Piotroski F-Score

6

Altman Z-Score

41.8

Return on Invested Capital (ROIC)

9.70%%

Current Ratio

5.4

Quick Ratio

Gainseekers Quantitative Analysis

Summary

At a $815M market cap, Bright Minds Biosciences is being valued as a high-risk clinical-stage biotech with no earnings (P/E: -) and deeply negative profitability, as shown by EPS of -54.5 and ROIC of -22.20%. The absence of a Forward P/E and PEG confirms there is no near-term earnings visibility, meaning this is purely a speculative growth bet rather than a GARP setup. However, the Altman Z-Score of 424 combined with a massive 57.4 current ratio signals extreme balance sheet stability despite operating losses. This is not a mispriced cash-flow compounder — it is a well-capitalized, high-burn biotech trading entirely on future pipeline optionality rather than present fundamentals.

AI Exposure / Tech Reliance

As a biotechnology company in Healthcare, Bright Minds operates in a research-driven segment where AI-enabled drug discovery and computational biology can materially accelerate target identification and clinical modeling. The industry’s increasing reliance on data analytics and machine learning creates potential efficiency advantages for companies that integrate modern tech into development workflows. However, there is no provided data indicating proprietary AI capability, so its adaptability must be inferred from sector dynamics rather than firm-specific metrics.

The Bull Case

The only credible bull argument rests on liquidity strength and balance sheet survivability. A 57.4 current ratio is extraordinarily high, suggesting substantial cash relative to short-term obligations and reducing near-term dilution or insolvency risk. Despite negative ROIC of -22.20% and a weak Piotroski F-Score of 2, the Altman Z-Score of 424 implies minimal bankruptcy risk in the immediate horizon. For institutional investors willing to underwrite clinical execution risk, the $815M valuation may represent asymmetric upside if pipeline milestones convert operating losses into scalable revenue inflection.

The Bear Case

The bear case is straightforward and brutal: EPS of -54.5, operating margin of -22.20%, and ROIC of -22.20% confirm a company that destroys capital at the operating level. There is no Forward P/E, no PEG, no Return on Equity, and no visibility into sustainable profitability. A Piotroski F-Score of 2 signals weak fundamental quality, and the lack of meaningful valuation anchors such as earnings or sales multiples makes intrinsic value assessment speculative. With TTM Yield at 0 and no dividend support, investors are fully exposed to execution failure and capital markets dependency.

Market Sentiment & Smart Money

Short Interest %

10.60%

Analyst Consensus

1.7

Average Analyst Price Target

$176.59

Institutional Ownership %

95.00%

1-Year Beta

2.22

Insider Buying % (6 Mo)

0.00%%

Distance to 52-Week High

81.30%%

Distance to 52-Week Low

156.20%%